Vorasidenib (AG-881)
CAS: 1644545-52-7
Ref. 3D-UQC54552
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Información del producto
Vorasidenib is a drug that has been approved for the treatment of adults with newly diagnosed glioblastoma. It is currently being investigated in preoperative settings, to see if it can reduce or eliminate the need for radiation therapy. Vorasidenib is an anti-angiogenic drug that blocks both vascular endothelial growth factor and platelet-derived growth factor receptors, which are key components of tumor angiogenesis. The drug has been shown to prolong survival in patients with malignant brain tumors and has few serious side effects. A multicenter phase II study showed a response rate of about 20% in patients with newly diagnosed gliomas who were given vorasidenib. Pharmacokinetic studies have demonstrated that vorasidenib crosses the blood-brain barrier and penetrates into the tumor cells at levels higher than other drugs used to treat gliomas.
Propiedades químicas
Consulta técnica sobre: 3D-UQC54552 Vorasidenib (AG-881)
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
